-
New in the Library (October-November 2024)
Here are the latest items added to the CTN Dissemination Library for October-November 2024 (this post will be updated as new items come in): Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention. Afshar M, et al. Journal of Addiction Medicine 2024;18(5):511-519. (CTN-0051) Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. Ross RK, et al. JAMA Network Open 2024;7(10):e2436612. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV, et al. American Journal of Psychiatry 2021;178(7):660-671. (CTN-0051) Examination of Correlates of OUD Outcomes in Young Adults:…
-
CTN T&I SIG Webinar: Implementation Outcomes in NIDA Clinical Trials Network Studies (Nov. 19, 9am PT)
Join the Translation and Implementation SIG on November 19th (9am-10am PT) for their next session, titled, “Implementation Outcomes in NIDA Clinical Trials Network Studies: A Systematic Review of Studies Conducted Over 25 Years in the CTN.“ This webinar will be presented by Sophia Gonzalez, MPH and Joe Glass, PhD, MSW of the CTN T&I Implementation Outcomes Workgroup and will focus on a study to explore and document the evolution of the inclusion of implementation outcomes across trials conducted within the CTN, characterize outcomes included, identify gaps and potential opportunities to strengthen implementation research within the CTN, and inform the broader field of SUD treatment. Contact Helene Chokron Garneau at hchokgar@stanford.edu…
-
New in the Library (September-October 2024)
Here are the latest items added to the CTN Dissemination Library for September– October 2024 (this post will be updated as new items come in): Falling Through the Cracks: The Struggle of Adolescents with Opioid Use Disorder in the Face of Limited Treatment Options. Kaliamurty S. Youth Special Interest Group (SIG) webinar, September 2024. Changes in Prenatal Cannabis Use Among Pregnant Individuals From 2012 to 2022. Young-Wolff KC, et al. Obstetrics & Gynecology 2024;144(4):e101-e104. Effectiveness of a Vaping Cessation Text Message Program Among a Diverse and High-Risk Sample of Adolescent E-Cigarette Users (webinar recording). Graham AL. Youth Special Interest Group (SIG) webinar, September 2024. Peer Intervention to Link Overdose Survivors…
-
News from the Health Systems Node
After 10 years of leadership as Project Director for the Health System Node, Andrea Altschuler, PhD is passing the torch to Monique Buffler, MPH. Fortunately, Andrea will continue to be involved in HSN with community engagement efforts. In her new role, Monique will assist MPIs with coordination and management of node activities. Kelly Young-Wolff, PhD, MPH, site PI with the Health System Node, and Research Scientist at the Kaiser Permanente Northern California Division of Research, was part of the National Academies of Science, Engineering and Medicine (NASEM) consensus panel who wrote the new report: Cannabis: Policy Impacts Public Health and Health Equity (2024). This report follows on the 2017 landmark…
-
Submit CPDD Paper/Poster Abstracts to CTN Publications Committee by November 29, 2024
CTN members: The receipt deadline for paper and poster abstracts for the June 2025 CPDD annual meeting is December 27, 2024. The Publication Committee would like to remind authors that presentations and poster abstracts should be submitted to the Publications Committee for prior review and approval at least a month in advance (November 29, 2024) of submission receipt deadline for CPDD. Due to holiday schedules, the PC cannot guarantee that we will be able to review and provide comments if these abstracts are not received by December 11th. Please be cognizant of holiday schedules of the PC and its reviewers and provide these CPDD abstracts for review as early…
-
News from the Big South/West Node
The Big South/West Node is pleased to announce that recruitment for CTN-0132 KMD has officially commenced. This randomized, double-blind, active placebo trial aims to investigate the use of IV ketamine versus midazolam in the treatment of methamphetamine use disorder (MUD). During the 12-week study, participants will receive cognitive behavior therapy (CBT). Currently, two sites are active, and we expect to endorse two additional sites by early November.
